Q2 2024 Earnings Forecast for Jasper Therapeutics, Inc. (NASDAQ:JSPR) Issued By HC Wainwright

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Investment analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.00) per share for the quarter, up from their prior estimate of ($1.36). HC Wainwright currently has a "Buy" rating and a $65.00 target price on the stock. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($5.02) per share. HC Wainwright also issued estimates for Jasper Therapeutics' Q3 2024 earnings at ($1.05) EPS, Q4 2024 earnings at ($1.22) EPS, FY2024 earnings at ($4.30) EPS, FY2025 earnings at ($5.07) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($6.88) EPS and FY2028 earnings at ($7.67) EPS.

JSPR has been the topic of a number of other reports. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an "outperform" rating on the stock. Royal Bank of Canada began coverage on Jasper Therapeutics in a research report on Thursday, March 28th. They issued an "outperform" rating and a $70.00 price target on the stock. Evercore ISI initiated coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an "outperform" rating and a $65.00 price target for the company. Finally, Oppenheimer restated an "outperform" rating and issued a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $64.29.

Jasper Therapeutics Stock Performance

JSPR traded up $0.18 during trading on Friday, hitting $23.02. The stock had a trading volume of 65,737 shares, compared to its average volume of 109,161. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The company has a 50 day simple moving average of $25.21 and a 200-day simple moving average of $15.62.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, topping analysts' consensus estimates of ($1.65) by $0.15.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Concurrent Investment Advisors LLC acquired a new position in shares of Jasper Therapeutics in the 1st quarter valued at $599,000. Fernwood Investment Management LLC raised its position in Jasper Therapeutics by 8.8% in the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company's stock worth $390,000 after purchasing an additional 40,000 shares in the last quarter. Forefront Analytics LLC lifted its stake in Jasper Therapeutics by 59.7% during the third quarter. Forefront Analytics LLC now owns 110,792 shares of the company's stock worth $78,000 after purchasing an additional 41,425 shares during the period. Ieq Capital LLC acquired a new position in shares of Jasper Therapeutics in the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Jasper Therapeutics in the 1st quarter worth approximately $2,343,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.